

Boston Scientific Provides Updates on TAXUS Sales and Financial Estimates for Second Half of 2004

(September 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today provided an update on the sales of its TAXUS™ Express²™ paclitaxel-eluting coronary stent systems for the month of August and financial estimates for the second half of 2004.

Preliminary worldwide sales of TAXUS systems for the month of August were approximately \$200 million. Preliminary U.S. sales for the month were \$157 million. Preliminary average daily U.S. sales for the month were in excess of \$7 million.

The Company estimates that its share of the U.S. drug-eluting stent market at the end of the month was in excess of 65 percent, on a reorder basis.

Sales for the third quarter are estimated to range between \$1.440 billion and \$1.465 billion, including worldwide TAXUS system sales of between \$594 million and \$608 million. Sales for the fourth quarter are estimated to range between \$1.510 billion and \$1.575 billion, including worldwide TAXUS system sales of between \$643 million and \$686 million. Sales for the year are estimated to range between \$5.492 billion and \$5.582 billion.

Earnings for the third quarter are estimated to range between \$0.45 and \$0.47 per share (diluted). Earnings for the fourth quarter are estimated to range between \$0.48 and \$0.51 per share (diluted). Earnings for the year, excluding net special charges, are estimated to range between \$1.60 and \$1.65 per share (diluted).

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, the regulatory process, competitive offerings, intellectual property, litigation, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.

<https://news.bostonscientific.com/updates-taxus-estimates-2h-2004>